Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents
Expert Opinion on Drug Safety – August 28, 2023
Source: OpenAlex
Summary
Psilocybin offers profound, lasting relief for mood disorders. In a clinical trial with 75 participants, 60% experienced significant depression symptom reduction for six months when guided by a psychotherapist. This Serotonergic compound, like lysergic acid diethylamide, influences neurotransmitter receptors, reshaping behavior. The field of Psychedelics and Drug Studies is re-evaluating these powerful hallucinogens. Advances in pharmacology and neuroscience, examining both natural alkaloids and those from chemical synthesis, are positioning them as a promising new medicine.
Abstract
KEYWORDS: Psychedelicpsilocybinlysergic acid diethylamidemood disordersantidepressantsdiscoverypharmacologyFDA